Current antiarrhythmic drugs for AF have limited ... and atrial remodeling. Class III drugs sotalol, dofetilide and ibutilide target reentry by prolonging the atrial effective refractory period ...

The Advantage AF study evaluated Farapulse in 260 patients who were drug intolerant to at least one Class I/III antiarrhythmic medication at 43 ... met the study’s primary safety endpoint with a 2.3% ...

1 Accident and Emergency Department, Ayr Hospital, Dalmellington Road, Ayr, Scotland 2 Accident ... Where antiarrhythmic agents are used it is important to avoid certain drugs that exacerbate the ...

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

NYHA class IV, New York Heart Association; SHFM, Seattle Heart Failure Model. Persistent haemodynamically compromising ventricular arrhythmias, refractory to all usual therapies (including ...

Squibb founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers invested $5000 into a struggling drug manufacturing firm in Clinton ...

AF at the time of PMC is associated with a decrease in survival without surgery or repeat PMC and with few or no symptoms (New York Heart Association class I–II ... ablation is more effective than ...

Abstract and Introduction Drugs Used for Ventricular Rate Control Drugs Used to Restore and Maintain Sinus Rhythm Conclusions References Although a large study [58] of over 1500 patients has ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Previously meant to be released in January 2025, Weak Hero Class 2 has been pushed back to a Q2 2025 release on Netflix. Weak Hero Class 2 is an upcoming South Korean Netflix Original action K-drama ...

Now, an analysis of studies has found that newer medications for type 2 diabetes may help reduce the risk of complications, particularly cardiovascular disease, in some people with type 2 diabetes.